Pfizer has received a formal approval from the European Commission for its Nyvepria (pegfilgrastim), giving the firm a pan-European marketing authorization for its biosimilar rival to Amgen’s Neulasta original.
The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September....



